Arvinas appoints new president and CEO; leadership transition announced
Source: SeekingAlpha
2026-02-12 08:13:34 ET
More on Arvinas
- Arvinas: Approvable, But Asset Looks Mediocre, Initiating With A Hold Rating
- Seeking Alpha’s Quant Rating on Arvinas
- Historical earnings data for Arvinas
- Financial information for Arvinas
Read the full article on Seeking Alpha
For further details see:
Arvinas appoints new president and CEO; leadership transition announced
Arvinas Inc.
NASDAQ: ARVN
ARVN Trading
-2.65% G/L:
$12.115 Last:
236,120 Volume:
$12.38 Open:
ARVN Latest News
March 11, 2026 07:00:00 am
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders
February 24, 2026 07:00:00 am
Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
ARVN Stock Data
$861,247,783
61,186,485
0.05%
68
N/A
Biotechnology & Life Sciences
Healthcare
US
New Haven
